Molecular design for enhancement of ocular penetration.
Over the past two decades, many oral drugs have been designed in consideration of physicochemical properties to attain optimal pharmacokinetic properties. This strategy significantly reduced attrition in drug development owing to inadequate pharmacokinetics during the last decade. On the other hand, most ophthalmic drugs are generated from reformulation of other therapeutic dosage forms. Therefore, the modification of formulations has been used mainly as the approach to improve ocular pharmacokinetics. However, to maximize ocular pharmacokinetic properties, a specific molecular design for ocular drug is preferable. Passive diffusion of drugs across the cornea membranes requires appropriate lipophilicity and aqueous solubility. Improvement of such physicochemical properties has been achieved by structure optimization or prodrug approaches. This review discusses the current knowledge about ophthalmic drugs adapted from systemic drugs and molecular design for ocular drugs. I propose the approaches for molecular design to obtain the optimal ocular penetration into anterior segment based on published studies to date.
Shirasaki
Yoshihisa
Y
Senju Pharmaceutical Co, Ltd, 1-5-4 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan. shirasaki@senju.co.jp
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D005123:Eye / Q000378:metabolism*; D006801:Humans; D007322:Instillation, Drug; D015394:Molecular Structure; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D010539:Permeability; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry; D012995:Solubility
D009883:Ophthalmic Solutions; D004364:Pharmaceutical Preparations